{"id":"NCT02210091","sponsor":"Baxalta now part of Shire","briefTitle":"BAX 855 Pediatric Study","officialTitle":"A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-31","primaryCompletion":"2015-10-23","completion":"2015-10-23","firstPosted":"2014-08-06","resultsPosted":"2016-12-05","lastUpdate":"2021-05-24"},"enrollment":75,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method","otherNames":["ADVATE"]},{"type":"BIOLOGICAL","name":"PEGylated Recombinant Factor VIII","otherNames":["BAX 855"]},{"type":"BIOLOGICAL","name":"PEGylated Recombinant Factor VIII","otherNames":["BAX 855"]}],"arms":[{"label":"<6 years old","type":"EXPERIMENTAL"},{"label":"≥6 to <12 years","type":"EXPERIMENTAL"}],"summary":"The study purpose is:\n\n* To assess the incidence of FVIII inhibitory antibodies during 6 months of twice weekly prophylactic treatment with BAX 855 or 50 exposure days (EDs), whichever occurs last.\n* To compare pharmacokinetic (PK) parameters to ADVATE.\n* To assess hemostatic efficacy in prophylaxis and the treatment of bleeding episodes.\n* To evaluate safety and immunogenicity.","primaryOutcome":{"measure":"Number of Participants With Inhibitory Antibodies to Factor VIII (FVIII)","timeFrame":"After first exposure to BAX 855 until completion of study - approx. 6 months per participant.","effectByArm":[{"arm":"<6 Years Old","deltaMin":0,"sd":null},{"arm":"6 to <12 Years Old","deltaMin":0,"sd":null},{"arm":"BAX 855 Safety Analysis Set","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":39,"countries":["United States","Bulgaria","Hong Kong","Malaysia","Netherlands","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["27891721"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":66},"commonTop":["Pyrexia","Upper Respiratory Tract Infection","Diarrhoea","Vomiting","Nasopharyngitis"]}}